THBS2 and metastatic colorectal cancer: As previously reported, patients with high TSP-2 saw a worse efficacy of FOLFIRI plus ramucirumab in terms of their RR, PFS, and OS in our study, so TSP-2 may still be a prognostic biomarker for metastatic colorectal cancer.